1. Washburn W. N. Meng W. Ellsworth B. A. Nirschl A. McCann P. J. Patel M. Girotra R. N. Wu G. Sher P. M. Biller S. A. Deshpande P. P. Hagan D. L. Taylor J. R. Obermeier M. Humphreys H. J. Khanna A. Robertson J. G. Wang A. Han S. P. Wetterau J. R. Janovitz E. Flint O. Whaley J. M.(2007).Synthesis and characterization of dapagliflozin a potent selective SGLT2 inhibitor for the treatment of diabetes. 234th ACS National Meeting MEDI028 Boston 19–23 August 2007.
2. Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
3. Committee for Medicinal Products for Human Use (CHMP)(2019).Summary of opinion (post authorisation) Forxiga dapagliflozin.https://www.ema.europa.eu/en/documents/smop/chmp‐post‐authorisation‐summary‐positive‐opinion‐forxiga‐ws‐1344_en.pdf(accessed April 19 2020).
4. SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects